Partners Alimera and pSivida have three times gone to the FDA with the eye drug Iluvien and three times walked away with little to show for it. But the fourth go-round will be different, the partners believe, and investors would seem to agree, sending the companies' shares skyward on renewed hopes for a 2014 approval.
The FDA has once more rejected Alimera Sciences and pSivida's drug-device combo for diabetic vision loss, roughly halving the companies' stock value and casting further doubt on a treatment plagued by years of failure
Alimera Sciences is facing an uphill battle getting its chronic diabetic macular edema drug on shelves in Europe, and now the company has recruited Quintiles to manage the European launch of Iluvien.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...
Smaller and more tightly focused will be the dominant style for Venrock Associates' new venture fund. The venture group--a busy player in the biotech space--says that it closed its new healthcare
Alpharetta, GA-based Alimera Sciences managed to buck a rough morning on Wall Street as its shares were buoyed by the announcement that the developer has submitted its lead therapy of diabetic
The biotech industry got a mixed read on investors' appetite for IPOs yesterday. The biotech Codexis launched its IPO at the low end of its price range on Wednesday, raising $78 million as it
Georgia-based Alimera Sciences is hoping to raise $87 million in an IPO, according to documents the company filed with the SEC today. The developer will offer 6 million shares at a price range of $15
Shares of pSivida rocketed up in overnight trading after investors got wind of the late-stage success of a new ophthalmic drug the biotech is co-developing with Alimera. The company reported that
Atlanta-based Alimera Sciences has refiled its IPO, upping the ante to $80 million as it tests investors' appetite for biotech stock. Alimera, which is developing new drugs for retina diseases,